Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study

NCT05158517 is registered in ClinicalTrials.gov with Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives as lead sponsor.

NCT NCT05158517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05158517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study
Lead sponsor
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Phase
Observational
Overall status
Unknown status
Start date
March 20, 2022
Completion date
March 20, 2025
Enrollment
349 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory bowel diseases